KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Receivables (2017 - 2025)

Historic Receivables for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $4.5 million.

  • Bionano Genomics' Receivables fell 1800.72% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 1800.72%. This contributed to the annual value of $4.9 million for FY2024, which is 5139.0% down from last year.
  • Latest data reveals that Bionano Genomics reported Receivables of $4.5 million as of Q3 2025, which was down 1800.72% from $3.6 million recorded in Q2 2025.
  • In the past 5 years, Bionano Genomics' Receivables ranged from a high of $10.1 million in Q4 2023 and a low of $3.5 million during Q1 2025
  • Moreover, its 5-year median value for Receivables was $6.0 million (2022), whereas its average is $6.2 million.
  • Its Receivables has fluctuated over the past 5 years, first surged by 11661.26% in 2021, then plummeted by 6039.35% in 2025.
  • Bionano Genomics' Receivables (Quarter) stood at $6.0 million in 2021, then grew by 29.58% to $7.8 million in 2022, then surged by 30.23% to $10.1 million in 2023, then crashed by 51.39% to $4.9 million in 2024, then dropped by 8.21% to $4.5 million in 2025.
  • Its Receivables stands at $4.5 million for Q3 2025, versus $3.6 million for Q2 2025 and $3.5 million for Q1 2025.